Across TCGA pan-cancer cohorts, PRKAR2A mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated PRKAR2A data layer compared with 27 for mass-spec protein and 4 for mutation status.
The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PRKAR2A mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated PRKAR2A expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.
LUAD are the cancer types where PRKAR2A mass-spec protein most reproducibly stratifies survival.